NYSE · RGEN
Healthcare · Medical - Instruments & Supplies
$176.89
Down-$1.30 (-0.73%)
Updated Sep 20, 2026, 11:40 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
RGEN closed at $176.89 after 19 trading sessions, down 2.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $179.10 | $179.10 | $176.29 | $176.89 | 1.36M |
| Sep 17, 2026 | $174.93 | $178.65 | $173.24 | $178.19 | 1.09M |
| Sep 16, 2026 | $174.90 | $178.55 | $171.66 | $172.91 | 826.9K |
| Sep 15, 2026 | $168.27 | $175.855 | $168.27 | $174.73 | 891.26K |
| Sep 14, 2026 | $166.74 | $168.42 | $162.10 | $168.00 | 514.4K |
| Sep 11, 2026 | $166.72 | $168.06 | $164.02 | $165.18 | 944.56K |
| Sep 10, 2026 | $162.68 | $165.04 | $161.1416 | $164.68 | 955.98K |
| Sep 9, 2026 | $168.53 | $169.52 | $162.46 | $165.05 | 1.08M |
| Sep 8, 2026 | $168.05 | $172.945 | $166.32 | $168.53 | 779.44K |
| Sep 4, 2026 | $167.26 | $169.51 | $165.00 | $167.60 | 806.07K |
| Sep 3, 2026 | $175.53 | $176.13 | $167.54 | $169.61 | 1.33M |
| Sep 2, 2026 | $171.765 | $176.87 | $168.58 | $172.94 | 959.33K |
| Sep 1, 2026 | $180.70 | $182.5692 | $167.42 | $170.02 | 1.41M |
| Aug 31, 2026 | $174.17 | $181.07 | $174.01 | $180.98 | 790.97K |
| Aug 28, 2026 | $179.76 | $181.345 | $175.695 | $176.27 | 818.72K |
| Aug 27, 2026 | $179.90 | $183.09 | $179.14 | $182.03 | 611.9K |
| Aug 26, 2026 | $180.11 | $183.43 | $179.465 | $180.30 | 539.1K |
| Aug 25, 2026 | $181.62 | $185.34 | $178.9812 | $181.69 | 1.14M |
| Aug 24, 2026 | $180.60 | $183.05 | $176.28 | $181.62 | 1.5M |
The latest Smart Investors Daily articles mentioning RGEN.
RGEN research
Company profile and research snapshot.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Yahoo · Sep 17, 2026
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
Yahoo · Sep 16, 2026
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
SeekingAlpha · Sep 11, 2026
2026-09-11. The following slide deck was published by Repligen Corporation in conjunction with this event.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGEN.
